|
A Study of Ipilimumab, Cabozantinib and Nivolumab in Rare Genitourinary Tumors (A031702) |
II |
|
|
A study of Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil/Leucovorin versus nab-paclitaxel plus Gemcitabine in subjects who have not previously recevied chemotherapy for metastatic adenocarcinoma of the pancreas (D-US-60010-001) |
III |
|
|
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) |
I |
|
|
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) |
I |
|
|
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) |
I |
|
|
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) |
I |
|
|
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) |
I |
|
|
A Study of Neoadjuvant Chemotherapy Alone vs Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab+BMS986205 Followed by Post Surgery Therapy with Nivolumab or Nivolumab+BMS986205 in Pts with Muscle Invasive Bladder CA (18095) |
III |
|
|
A Study of NKTR-262 in Combination with NKTR-214 and with NKTR-214 Plus Nivolumab In Patients with Locally Advanced or Metastatic Solid Tumors of Urothelial or Renal Origin (REVEAL) |
|
|
|
A Study of Osimertinib in Advanced NonSmall Cell Lung Cancer Patients with Exon20 Mutations in EGFR (EA5162) |
II |
|
|
A Study of Pembrolizumab + Olaparib vs Abiraterone or Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (MK7339-010) |
III |
|
|
A Study of Pembrolizumab and Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (GY016) |
II |
|
|
A study of PF06821497 in the treatment of adult patients with relapsed/refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma (C2321001) |
I |
|
|
A study of PF06821497 in the treatment of adult patients with relapsed/refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma (C2321001) |
I |
|
|
A study of PF06821497 in the treatment of adult patients with relapsed/refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma (C2321001) |
I |
|
|
A Study of REGN5678 with Cemiplimab in Patients with Metastatic Castration Resistant Prostate Cancer (R5678-ONC-1879) |
I |
|
|
A Study of Regorafenib and Anti-PD-1 in Patients with Microsatellite Stable Colorectal Cancer (19096) |
II |
|
|
A Study of Sitravatinib in Combination with Nivolumab vs Docetaxel in Patients with Advanced Nonsquamous Nonsmall Cell Lung Cancer with Disease Progression on or after Platinum Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy(MRT516005) |
III |
|
|
A Study of the Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (MT-3724NHL001) |
|
|
|
A study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (GOG-3029) |
|
|
|
A Study Testing the Addition of the Antibody Atezolizumab to Chemotherapy with Liposomal Doxorubicin and Bevacizumab in Recurrent Ovarian Cancer (GY009) |
|
|
|
A Study to Evaluate Ribociclib in Combination with NonSteroidal Aromatase Inhibitor for the Treatment of Women with Advanced Breast Cancer Who have Received No Prior Therapy (19004) |
II |
|
|
A study to evaluate subcutaneous Daratumumab in combination with stafnard mutliple myeloma treatment regimens (54767414MMY2040) |
II |
|
|
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) |
III |
|
|
A treatment protocol of Tucatinib in combination with Capecitabine and Trustuzumab in patients with previously treated unresectable locally advanced or metastatic HER2+ breast carcinoma (SGNTUC-021) |
|
|
